Ascendis Pharma A/s vs TG Therapeutics
Ascendis Pharma A/s is the larger business, with $814m of revenue in fiscal 2025 against $616m for TG Therapeutics (1.3 times as much). Ascendis Pharma A/s grew faster (106.9% against 87.3%). TG Therapeutics kept more of each dollar of sales as profit: a net margin of 72.6% against -31.7%.
| Latest fiscal year | Ascendis Pharma A/sASND, 2025 | TG TherapeuticsTGTX, 2025 |
|---|---|---|
| Revenue | $814m | $616m |
| Revenue growth | 106.9% | 87.3% |
| Net income | −$258m | $447m |
| Operating margin | -18.9% | 20.0% |
| Net margin | -31.7% | 72.6% |
| Return on equity | — | 102.8% |
| Free cash flow | $60.9m | −$25.0m |
| Cash | $723m | $79.1m |
| Total debt | $956m | $246m |
| Debt to equity | — | 37.9% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $19.7m | $91.2m |
| Employees | — | 399 |
| Market value | $15.18bn | $9.32bn |
| Price vs our value range | — | — |
| Moat score | — | 9 (Weak) |
| Insider trades, 12 months | 9 buys, 3 sales | 0 buys, 2 sales |